HOPA's Practice Outcomes and Professional Benchmarking Committee (POPBC) conducted a multi-organization, voluntary survey of HOPA members between March of 2021 and January of 2022. The purpose was to better understand the landscape of oncology pharmacy at healthcare organizations throughout the United States.

The research examined: institutional description, job function, staffing, and training/certification. Data were evaluated using descriptive statistics. The analysis found that as the number of patients with cancer rises, the oncology workforce must grow. The current oncology pharmacy practice landscape can serve as a foundation for future research, metrics, and benchmarks.

This research was published in the Journal of Oncology Pharmacy Practice.


Authors: Shawn P Griffin, Jessie R Signorelli, Aubrey Lasko, Benjamin J Andrick, David Doan, Shannon Hough, Grazyna Riebandt, and Stephen Harnicar

Pharmacist’s Application to Practice: Niraparib and Abiraterone Acetate (Akeega™)

Mallori Anderson, PharmD, PGY2 and Christine Barrett, PharmD, BCOP, from the Mary Babb Randolph Cancer Center write about Akeega™

Pharmacist's Application to Practice: Elranatamab-bcmm

Emily Lo, PharmD Candidate and Chung-Shien Lee, PharmD, BCPS, BCOP at St John’s University College of Pharmacy and Health Sciences write about Elranatamab-bcmm).

Pharmacist’s Application to Practice: Talquetamab-tgvs

Marguerite Courtney, PharmD Candidate 2024 and Bradley Yelvington, PharmD, BCOP from University of Tennessee discuss talquetamab-tgvs